10x Genomics, Inc.
Moat Score — 10x Genomics, Inc.
Total Moat Score
13 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | 10x Genomics holds a deep patent portfolio around single-cell partitioning and spatial biology chemistry, and has been active in defending it through litigation, giving it real but contestable IP protection against both established and emerging competitors. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | 10x Genomics does not have a structural manufacturing cost advantage over larger diversified life-science tool makers like Illumina or Thermo Fisher, which can leverage broader scale and shared infrastructure across many product lines. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 2 / 5 | Rising gross margin (69% in FY2025 versus 68% in FY2024) suggests some ability to maintain pricing on a maturing consumables base, but intensifying spatial-biology competition from NanoString/Bruker and Vizgen limits how much further pricing power can expand. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 1 / 5 | There is a modest ecosystem effect as more published single-cell and spatial research using 10x platforms encourages other labs to standardize on the same tools for comparability, but this is a soft, indirect effect rather than a true network effect. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 4 / 5 | The razor-and-blade model creates strong switching costs: once a lab has purchased a Chromium or Xenium instrument, validated protocols around it, and trained staff, switching to a competing platform means re-purchasing capital equipment and re-validating workflows, which anchors recurring consumables revenue to the installed base. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 2 / 5 | Single-cell and spatial biology is a large and growing but still maturing market that supports several well-funded competitors (Parse Biosciences, Scale Bio, NanoString/Bruker, Vizgen), so 10x's scale is meaningful but not yet a decisive, scale-limited barrier to entry. |